Top Medical Searches

New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK(telaprevir) in Hepatitis C

- High viral cure rate achieved with a 24-week INCIVEKcombination regimen -CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep 14, 2011 – VertexPharmaceuticals Incorporated (Nasdaq: VRTX) today announced thatthe New England Journal of Medicine (NEJM)…


 Read more…

Be Sociable, Share!
September 14th, 2011 Posted in Drug
Copyright 2008 © Drugs and Diseases. Developed by Axilosoft
Home | About Us | Privacy Policy | Contact Us